Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

Published:2018-02 Issue:2 Volume:5 Page:e73-e81
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Harrison Claire N,Vannucchi Alessandro M,Platzbecker Uwe,Cervantes Francisco,Gupta Vikas,Lavie David,Passamonti Francesco,Winton Elliott F,Dong Hua,Kawashima Jun,Maltzman Julia D,Kiladjian Jean-Jacques,Verstovsek Srdan

Publisher

Elsevier BV

Subject

Hematology

Reference15 articles.

1. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology;Mesa;J Natl Compr Canc Netw,2016

2. bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment;Tefferi;Mayo Clin Proc,2005

3. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms;Tyner;Blood,2010

4. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients;Pardanani;Leukemia,2009

5. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents;Asshoff;Blood,2017

Cited by 231 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Stem Cell Transplantation for Myelofibrosis;Current Hematologic Malignancy Reports;2024-09-06

2. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial;The Lancet Haematology;2024-09

3. SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis;Clinical Lymphoma Myeloma and Leukemia;2024-09

4. Comparative efficacy and hematologic safety of different dosages of JAK inhibitors in the treatment of myelofibrosis: a network meta-analysis;Frontiers in Oncology;2024-08-30

5. Momelotinib in myelofibrosis and beyond: a comprehensive review of therapeutic insights in hematologic malignancies;Discover Oncology;2024-08-27